课题基金 / 基金详情

项目摘要

项目成果

Kristin Tarbell的其他基金

相似基金

相关文献

中文摘要
翻译
在过去的一年里,我们完成了对临床方案结果的计划分析,评估了DPP-4特异性抑制剂(Sitagliptin/Januvia)对健康个体免疫功能的影响。我们的分析表明,西格列汀不会显著改变我们测量的大多数免疫读数,包括血浆转化生长因子-β和其他细胞因子的水平,以及PBMC上的流式细胞术。收集的流式细胞仪数据包括Treg分析和淋巴细胞亚群上CD26的表达。我们确实观察到西格列汀治疗后早期CD26表达的微小但显著的变化,但这些变化不是持续的,因此不太可能与临床相关。这项研究已经被接受出版。
英文摘要
In the past year, we have completed planned analysis of results from the clinical protocol, Assessment of the Effects of A DPP-4-Specific Inhibitor (Sitagliptin/Januvia) on Immune Function in Healthy Individuals. Our analysis has indicated that sitagliptin does not significantly alter most of the immune readouts we measured, including levels of plasma TGF-beta and other cytokines, and flow cytometry on PBMCs. Flow cytometry data collected include Treg analysis and expression of CD26 on lymphocyte subsets. We did observe small but significant changes in CD26 expression early after sitagliptin treatment, but these changes were not sustained, and therefore are not likely to be clinically relevant. This study has been accepted for publication.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
dendrtitic cell subsets in autoimmune diabetes
Dendritic cell subsets in autoimmune diabetes
testing the effect of a DPP-4 inhibitor on immune function
Dendritic cell subsets in autoimmune diabetes
海外基金